外科理论与实践

外科理论与实践 >

2026 , Vol. 31 >Issue 02: 108 - 113

DOI: https://doi.org/10.16139/j.1007-9610.2026.02.03

专家论坛

结直肠癌化疗：基石地位巩固与精准化发展

  • 姚望 ,
  • 张俊
展开
  • 上海交通大学医学院附属瑞金医院肿瘤科， 上海市胃肿瘤重点实验室， 上海 200025
作者贡献/Authors’ contributions

姚望负责资料收集和撰写；张俊负责指导、审查和修订。所有作者均阅读并确认最终稿。

张俊, E-mail: junzhang10977@sjtu.edu.cn

收稿日期: 2026-01-09

  网络出版日期: 2026-06-23

基金资助

国家自然科学基金(82573607);国家自然科学基金(82273126)

收起

Chemotherapy for colorectal cancer: consolidation of the cornerstone and advances in precision

  • YAO Wang ,
  • ZHANG Jun
Expand
  • Department of Oncology, Shanghai Key Laboratory of Gastric Cancer, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2026-01-09

  Online published: 2026-06-23

Fold

摘要

作为结直肠癌系统性治疗的基石，化疗（细胞毒性药物治疗）在临床实践中的应用持续精进，范围扩大。在晚期疾病治疗中，化疗与靶向、免疫药物的联合方案不断优化，形成针对不同分子亚型的精准治疗策略，显著提升疗效。在围术期治疗领域，新辅助化疗、全程新辅助治疗(TNT)的应用，以及辅助化疗的精准升级，正在重塑可切除结直肠癌病人的治疗格局。此外，循环肿瘤DNA (ctDNA)等新技术为临床决策及化疗疗效的预测与动态监测提供了可能。本文以化疗为视角，系统解析其参与结直肠癌治疗体系的作用，并探讨其临床挑战与未来方向。

关键词： 结直肠癌; 化疗; 新辅助治疗; 辅助治疗; 姑息治疗

本文引用格式

姚望 , 张俊 . 结直肠癌化疗：基石地位巩固与精准化发展[J]. 外科理论与实践, 2026 , 31(02) : 108 -113 . DOI: 10.16139/j.1007-9610.2026.02.03

Abstract

As the cornerstone of systemic treatment for colorectal cancer, chemotherapy (cytotoxic drug therapy) continues to evolve in clinical practice, with its scope and application significantly expanding. In the treatment of advanced disease, the combination of chemotherapy with targeted and immunotherapeutic agents has been continuously optimized, leading to the development of precision treatment strategies tailored to different molecular subtypes, which has markedly improved therapeutic efficacy. In the field of perioperative therapy, the application of neoadjuvant chemotherapy, total neoadjuvant therapy (TNT), and the precision enhancement of adjuvant chemotherapy are reshaping the treatment landscape for patients with resectable colorectal cancer. Furthermore, novel technologies such as circulating tumor DNA offer the potential for prediction and dynamic monitoring of clinical decision and chemotherapy efficacy. From the perspective of chemotherapy, this article systematically analyzed its role in the treatment system for colorectal cancer, and discussed its clinical challenges and future directions.

Key words： Colorectal cancer; Chemotherapy; Neoadjuvant therapy; Adjuvant therapy; Palliative treatment

参考文献

[1] XIA C, DONG X, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J, 2022, 135(5):584-590.
[2] CIARDIELLO F, CIARDIELLO D, MARTINI G, et al. Clinical management of metastatic colorectal cancer in the era of precision medicine[J]. CA Cancer J Clin, 2022, 72(4):372-401.
[3] MORTON D, SEYMOUR M, MAGILL L, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial[J]. J Clin Oncol, 2023, 41(8):1541-1552.
[4] SHIOZAWA M, SUNAKAWA Y, WATANABE T, et al. Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase Ⅱ DEEPER trial[J]. Nat Commun, 2024, 15(1):10217.
[5] YEKU O O, LONGO D L. Combination therapy, including bevacizumab, for advanced colorectal cancer[J]. N Engl J Med, 2023, 388(18):1711-1714.
[6] CHAPIN W J, HWANG W, MAMTANI R, et al. Low- vs. high-dose 5-FU in triplet chemotherapy plus bevacizumab for patients with colorectal cancer[J]. JAMA Netw Open, 2024, 7(7):e2424855.
[7] GRUENBERGER T, BRIDGEWATER J, CHAU I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase Ⅱ trial[J]. Ann Oncol, 2015, 26(4):702-708.
[8] BOND M J G, BOLHUIS K, LOOSVELD O J L, et al. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group[J]. Lancet Oncol, 2023, 24(7):757-771.
[9] DING K F, LIU Y, ZHANG Y Q, et al. Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: a multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial)[J]. J Clin Oncol, 2025, 43(17_suppl):LBA3502.
[10] LIU T S, XU R H, WANG F, et al. Subgroup analysis of efficacy and safety of fruquintinib plus paclitaxel versus paclitaxel in gastroesophageal junction adenocarcinoma patients from FRUTIGA: a randomized phase 3 clinical trial in second-line treatment of gastric/gastroesophageal junction adenocarcinoma[J]. J Clin Oncol, 2025, 43(16_suppl):e16012.
[11] STAHLER A, KARTHAUS M, FRUEHAUF S, et al. Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial[J]. EClinicalMedicine, 2024,79:103004.
[12] SHI Y, BA Y, WANG J, et al. First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a rando-mized, phase 3 trial[J]. Signal Transduct Target Ther, 2025, 10(1):147.
[13] MARGONIS G A, BUETTNER S, ANDREATOS N, et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer[J]. JAMA Surg, 2018, 153(7):e180996.
[14] KOPETZ S, YOSHINO T, VAN CUTSEM E, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial[J]. Nat Med, 2025, 31(3):901-908.
[15] HONG D S, FAKIH M G, STRICKLER J H, et al. KRASG12C inhibition with sotorasib in advanced solid tumors[J]. N Engl J Med, 2020, 383(13):1207-1217.
[16] ANDRé T, SHIU K K, KIM T W, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. N Engl J Med, 2020, 383(23):2207-2218.
[17] ANDRE T, ELEZ E, VAN CUTSEM E, et al. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer[J]. N Engl J Med, 2024, 391(21):2014-2026.
[18] CONROY T, BOSSET J F, ETIENNE P L, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(5):702-715.
[19] GANI C, FOKAS E, POLAT B, et al. Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2025, 10(6):562-572.
[20] CONROY T, CASTAN F, ETIENNE P L, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial[J]. Ann Oncol, 2024, 35(10):873-881.
[21] DOU X, ZHAO L, MA Z, et al. Total neoadjuvant therapy integrating long-course radiotherapy with trifluridine/tipiracil for locally advanced rectal cancer: a single-arm, multicenter phase 2 trial[J]. EClinicalMedicine, 2025,85:103312.
[22] CHEN E Y, NABAVIZADEH N, KENDSERSKY N D, et al. Phase Ⅰb study to assess the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage Ⅱ/Ⅲ rectal cancer: the fierce study[J]. Clin Colorectal Cancer, 2026:S1533- 0028(26)00008-3.
[23] HE W, HUANG J, LIAO G X, et al. Short-course radiation (SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 as neoadjuvant therapy for patients with locally advanced rectal cancer (LARC): a multicenter, single arm, phase Ⅱ trial (NeoCaCRT)[J]. J Clin Oncol, 2025, 43(4_suppl):LBA210.
[24] TIAN F, DAI H, SHA D, et al. Total neoadjuvant treatment with short-course radiotherapy followed by sinti-limab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial[J]. Lancet Oncol, 2025, 26(8):1043-1054.
[25] LIN Z Y, ZHANG P, CHI P, et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase Ⅲ trial[J]. Ann Oncol, 2024, 35(10):882-891.
[26] WANG F, CHEN G, ZHANG Z, et al. The Chinese Socie-ty of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update[J]. Cancer Commun (Lond), 2025, 45(3):332-379.
[27] NOWAK J A, SHI Q, TWOMBLY T, et al. Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage Ⅲ colon cancer treated with celecoxib: findings from CALGB (Alliance)/SWOG 80702[J]. J Clin Oncol, 2025.
[28] TIE J, WANG Y, LOREE J M, et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-Ⅲ trial[J]. Nat Med, 2025, 31(12):4291-4300.
[29] CHEN R, LI R, YANG Z, et al. Pressurized intraperitoneal aerosol chemotherapy in advanced colorectal cancer with peritoneal metastases: a meta-analysis of feasibility, efficacy, and safety[J]. Holist Integr Oncol, 2025, 4(1):60.
Options
文章导航

/

〈 〉